Latest research on BPC-157
A rolling research summary page that can be updated as new papers or reviews emerge.
Category
Research Updates
All published pages assigned to the Research Updates category.
When obesity meds get blamed in the OR
A perioperative review argues that adverse effects from modern anti-obesity drugs can be mistaken for surgical or anesthesia complications, raising the bar for documentation, holds, and post-op restarts.
A virus-mimicking peptide that pushes mRNA beyond the liver
Researchers describe an enveloped virus-mimicking particle built from a simplified peptide plus tuned lipids, aiming for repeatable mRNA delivery to extrahepatic tissues like lung and spleen.
Donkey-milk exosomes for oral octreotide
A new mouse study tests an exosome-based ‘biomimetic’ delivery idea for oral octreotide, hinting at a path beyond permeability enhancers but leaving big manufacturing and translation questions.
A dose-linked mental health signal for semaglutide
A large EHR-based preprint links semaglutide to lower rates of many neuropsychiatric diagnoses, with a ‘legacy’ signal that tracks maximum achieved dose more than weight loss.
GLP‑1 drugs and atrial fibrillation risk
A new observational study links GLP‑1 therapy to lower atrial fibrillation risk even when people do not lose weight, with the strongest signal reported for semaglutide.
GLP‑1 plus SGLT2 in fatty liver disease
A large real-world analysis links GLP‑1 plus SGLT2 combination therapy to lower rates of major liver and cardiovascular events in people with fatty liver disease and type 2 diabetes.
How vosoritide looks after one year
A new meta-analysis pools one-year results for vosoritide in children with achondroplasia, clarifying typical growth changes and the most common side effects.
Rosuvastatin may briefly blunt post-meal GLP‑1
A translational study links cholesterol-pathway inhibition (HMGCR/rosuvastatin) to lower acute GLP‑1 secretion in gut cells and mice, offering a plausible mechanism behind statins’ mild diabetes signal.
A sublingual peptide vaccine for gingipain
A mouse study engineers a sublingual nanovaccine that combines a gingipain antigenic peptide with CpG adjuvant inside a tetrahedral DNA scaffold and hydrogel, boosting salivary IgA and reducing periodontitis signs.
GLP‑1 drugs during chemo: the monitoring gap
A new supportive-care commentary argues that as GLP‑1 drugs become common, cancer treatment teams may need routine nutrition and body-composition monitoring to avoid avoidable toxicity and dose changes.
Why SNAC’s chemistry may be the hidden variable in oral peptide pills
A new mechanistic study shows SNAC, the absorption enhancer used in oral semaglutide, changes state with pH, salts, bile, and co-medications—conditions that may shape oral peptide consistency.
GLP‑1 use before burns linked to lower mortality
A large matched TriNetX study found prior GLP‑1 receptor agonist exposure was associated with fewer infections, less ICU care, and lower mortality after smaller thermal burns, but it cannot prove cause and effect.
A new look at GLP‑1s and suicidality risk
A large register study using two comparator cohorts plus a self-controlled design found no increased rate of suicide or suicide attempts after starting GLP‑1 receptor agonists.
Amylin may shape anxiety and sociability, differently by sex
A rat study links the pancreatic hormone amylin to anxiety-like behavior, aggression, and sociability, with the central amygdala driving some effects in opposite directions in males and females.
A neural clue for GLP-1 drugs’ heart rate bump
In an in vitro rat brainstem-spinal cord setup, exendin-4 increased sympathetic nerve activity and depolarized key neurons, supporting a direct neural route for GLP-1 receptor agonist tachycardia.
A barcode-free way to find permeable macrocycles
A Nature Communications paper introduces CycloSEL, a mass spectrometry driven workflow that screens fully synthetic macrocycle libraries and reports an intracellular-target hit later optimized for permeability.
Diffusion models get better at cyclic peptides
A 2026 paper retrains an all-atom diffusion model to generate accurate conformers for small cyclic peptides, including noncanonical amino acids and complex linkages, with a practical stereochemistry correction step.
A five-minute sublingual window for a GLP‑1 peptide
In diabetic mice, a long-acting, fatty-acid–conjugated GLP-1 receptor agonist showed measurable effects when held under the tongue for about five minutes after the team tuned pH and excipients.
A new antifungal idea: random peptide mixtures
A bioRxiv preprint reports that a ‘random peptide mixture’ called FK20 can hit multiple fungal pathogens, disrupt biofilms, and show mouse efficacy, with a potentially lower resistance footprint.
A bispecific peptide-drug conjugate for tumor macrophages
A peptide-drug conjugate blocks PD‑L1 and LAG‑3 and conditionally releases a TLR7/8 agonist in tumors, aiming to repolarize macrophages and boost T-cell activity with less systemic toxicity.
Yeast display finds tight-binding ACE2 macrocycles
A Journal of Medicinal Chemistry study uses yeast display to screen millions of disulfide-cyclized peptides and turns up low‑nanomolar inhibitors of human ACE2, backed by crystal structures.
A new trick for shorter LL-37 antibiotics
A preprint suggests a simple chemical add-on can make a short LL-37 fragment more bacteria-killing, hinting at a reusable design rule for antimicrobial peptides.
MOTS-c levels in teen PCOS look similar
In a small 2026 study of teens, blood levels of the peptide MOTS-c looked broadly similar in polycystic ovary syndrome and controls, and a tested mitochondrial variant was not seen in this group.
AMG 133 and the antibody-peptide obesity strategy
Researchers describe AMG 133, an antibody-peptide conjugate designed to combine GIP receptor antagonism with GLP-1 receptor agonism. It’s a design story about longer-acting multi-target biology, not a new approved therapy.
A peptide gel to help bladder cancer immunotherapy
A mouse study reports an enzyme-responsive peptide that forms a bladder-local hydrogel depot to retain BCG longer, aiming to reduce washout and improve immune activation in non-muscle-invasive bladder cancer.
A bicyclic peptide that targets a cancer integrin
Researchers report a bicyclic peptide isomer (10‑Mansa) that selectively inhibits integrin αvβ6 and shows prolonged tumor enrichment in preclinical work, highlighting how 3D peptide shape can make or break targeting.
A peptide signal for cartilage repair
In osteoarthritic human chondrocytes, a BMP7-derived peptide (p[63–82]) shifted gene expression toward collagen assembly pathways and increased glycosaminoglycan content. A repair-flavored signal in human cells, not a joint therapy yet.
A pregnancy peptide tied to fetal heart defects
A study in humans and mice links lower ELABELA (ELA) levels to congenital heart disease and suggests a mitochondria-related mechanism in cardiac development. Promising as a biomarker lead, not a clinical test yet.
Which GLP-1 drugs lead on weight loss
A network meta-analysis of phase 3 trials in adults without diabetes found all three major GLP-1 era weight-loss drugs reduced weight vs placebo, with higher-dose tirzepatide ranking highest on average.
A new AI model for finding BBB-crossing peptides
A 2026 Advanced Science paper introduces INB3P, a machine-learning framework built for small peptide datasets. It predicts blood-brain barrier-penetrating motifs and offers interpretability tools, but still needs prospective validation.
A precision commensal that makes phosphorylated lantibiotics to suppress oral pathogens
An NPJ Biofilms & Microbiomes paper reports that a Streptococcus salivarius strain (SALI-10) produces phosphorylated lantibiotics (pLANs), can engraft into dysbiotic human-derived oral biofilms, suppress periopathogens, and shows a small first-in-human feasibility signal after 1 week of daily dosing. It’s early, but it’s a concrete example of peptide-like natural products paired with a ‘live’ delivery vehicle.
A beta cell-targeted PD‑1 agonist for type 1 diabetes
A Science Advances paper describes a bispecific ‘ImmTAAI’ molecule that binds a preproinsulin peptide–HLA complex on beta cells and delivers a PD‑1 agonist signal to suppress autoreactive T cells locally in human pancreas slice models. It’s early, but it’s an unusually concrete example of tissue-targeted immunomodulation in type 1 diabetes.
An umbrella review asks: do GLP‑1 drugs help heart failure?
A 2026 umbrella review of prior meta-analyses reports GLP‑1 receptor agonists are associated with lower major adverse cardiovascular events and less ‘worsening heart failure’, plus a small improvement in 6‑minute walk distance. Mortality and heart-failure hospitalization results were not clearly improved, and evidence certainty ranged low to moderate.
A new trick for peptides to enter cells
Researchers report benzaldehyde-tagged cell-penetrating peptides can anchor to membrane proteins via reversible imine chemistry, helping cargo escape endosomes and reach the cytosol.
Two immune peptides team up against bacteria
A new mechanistic study suggests LL-37 and HNP1 can form reversible aggregates that become more active on bacterial-like membranes while staying less toxic to human cells.
A bacterial ‘lipoprotein’ machine can be repurposed to build lipidated macrocyclic peptides
A 2026 PNAS paper reports a way to co-opt bacterial lipoprotein processing to biosynthesize lipidated macrocyclic peptides. It is a methods advance that could matter for lipopeptide discovery and tuning pharmacology.
VIP may push renal cancer cells toward autophagy and cell death (preclinical)
A 2026 preclinical paper reports vasoactive intestinal peptide (VIP) can induce autophagy and cytotoxicity in renal cell carcinoma models, with a proposed SIRT3-dependent mechanism. Interesting biology, far from a therapy.
Antibody-inspired bicyclic peptides target the conserved influenza HA stem
A 2026 PNAS paper reports constrained bicyclic peptides, inspired by the FI6v3 antibody HCDR3, that bind the conserved hemagglutinin stem and neutralize multiple influenza A subtypes in vitro.
A human skin peptide that blocks influenza
A PNAS study reports that dermcidin, an antimicrobial peptide found in sweat, can bind influenza hemagglutinin, inhibit infection in vitro, and protect mice, with higher levels seen in asymptomatic humans.
LEAP2 curbed appetite in men with obesity
In a small randomized crossover study, an intravenous infusion of LEAP2, an endogenous ghrelin receptor antagonist, reduced ad libitum food intake and lowered post-meal glucose in men with obesity.
GLP-1 drugs and depression: a meta-analysis finds a signal, but the heterogeneity is huge
An open-access meta-analysis reports higher odds of depression-related adverse events among GLP-1 receptor agonist users (OR 1.49), but between-study heterogeneity is extreme (I² ~99%), which limits how literally the pooled number should be taken.
SURPASS-CVOT post hoc: broader cardiorenal outcomes favor tirzepatide vs dulaglutide
A post hoc analysis of SURPASS-CVOT expands the endpoint list beyond classic MACE. In patients with type 2 diabetes and established CVD, tirzepatide was associated with fewer composite cardiovascular + kidney events than dulaglutide, with more GI side effects.
GLP-1 drugs and thyroid labs: a quiet monitoring gap
A Medicare target-trial emulation found similar thyroid-stimulating hormone (TSH) testing patterns after GLP-1 receptor agonist initiation versus SGLT-2 inhibitors in older adults on stable levothyroxine, despite weight loss often changing thyroid hormone requirements.
A new tirzepatide safety meta-analysis, focused on higher-risk patients
A systematic review and meta-analysis of 21 placebo-controlled trials in patients at increased cardiovascular risk found no clear difference in serious adverse events with tirzepatide, while gastrointestinal side effects remained more common. Mortality evidence was sparse.
A mitochondria-targeted peptide for optic nerve injury
In a mouse optic nerve crush model, the research peptide HDAP2 was associated with less mitochondrial loss in injured axons and higher retinal ganglion cell survival. Early preclinical neuroprotection, not a human result.
A sharp-edged cyclic peptide with antimalarial activity
Lyngbyabellin Q, a marine cyanobacterial cyclic peptide, showed potent in vitro antimalarial activity but also signals actin-related cytotoxicity. A classic ‘potent but sharp’ natural-products starting point.
A tiny amino acid tweak that can help peptides go oral
A medicinal-chemistry study suggests one residue, Aib, can sometimes ‘pre-organize’ macrocyclic peptides so they cross membranes more easily, improving oral exposure in mice. It is scaffold-dependent, not magic.
A cyclic peptide shows antifibrotic promise in mice
Researchers took an antimicrobial peptide, tightened it into a drug-like cyclic version (CYP9), and reported reduced lung-fibrosis signaling in preclinical models. Early, but a useful example of peptide engineering.
Do GLP‑1 drugs help heart failure symptoms?
A new randomized-trial meta-analysis (preprint) finds the ‘hard outcome’ signal in heart failure is not clean, but people with HFpEF and obesity report better symptoms and walk a bit farther on GLP‑1 drugs.
A peptide that helps teeth lay down new dentine
Researchers carved a tiny 12–amino acid fragment from a tooth-development protein and found it promoted ‘reparative dentine’ formation in a rat pulp-capping model. Early, but a nice example of protein-to-peptide simplification.
Pancreatitis fears and GLP‑1s: the cleanest data so far
A living meta-analysis of placebo-controlled RCTs of semaglutide and tirzepatide lands near ‘no signal’ for acute pancreatitis. That’s reassuring, but rare-event uncertainty is exactly why this concern keeps coming back.
Surgery still outperforms GLP‑1 drugs over longer follow-up
A meta-analysis comparing bariatric surgery with GLP‑1 drugs found the gap widened as follow-up got longer. The signal is strong, but still confounded by non-random treatment selection and real-world access differences.
For short bowel syndrome, GLP‑2 drugs work—and the side effects matter
A 2026 review of glucagon-like peptide therapies in short bowel syndrome puts the spotlight where patients live: side effects, monitoring, and the trade-offs that come with reducing dependence on IV nutrition.
Japan’s real-world 177Lu‑DOTATATE cohort gives PRRT a scale check
A nationwide multicenter retrospective study from Japan (422 patients, 33 institutions) reports real‑world outcomes for 177Lu‑DOTATATE PRRT in advanced neuroendocrine neoplasms. Response and progression-free survival look broadly consistent with PRRT’s established role, with useful predictor breakdowns.
Osteoarthritis isn’t just wear-and-tear. A ‘resolution’ peptide is one way to treat what’s left
A 2026 mouse study reports that Ac2‑26, an Annexin A1–derived pro‑resolving peptide, reduced pain-like sensitivity and several joint damage readouts in collagenase-induced osteoarthritis. It’s preclinical—but it illustrates the logic of “resolution pharmacology.”
Why CRAB still needs new antibiotics: lachnospirin‑1 as an early lead
A 2026 *Virulence* paper reports that lachnospirin‑1 killed carbapenem-resistant *A. baumannii*, disrupted biofilms and persisters, and showed efficacy in mouse infection models. It is still preclinical, but it has the kind of signal package that can justify deeper development.
Why many peptide breakthroughs fail in synthesis
A 2026 Nature Chemistry paper suggests overall amino acid composition, more than specific motifs, can predict when peptides will aggregate on-resin during solid-phase synthesis. If it generalizes, it could turn synthesis guesswork into planning.
A ‘next‑gen BPC‑157’ is trending. Here’s how to verify ‘pentadecapeptide arginate’ before treating it as real
“Pentadecapeptide arginate” is being promoted online as a stabilized, enhanced BPC‑157 analog. The clean way to read the trend is as a verification exercise: what exactly is the compound, what evidence exists, and what would need to be true for the marketing claims to be more than adjectives.
A peptide-coated graft and the race to re-create a blood vessel’s inner lining
A 2026 Biomaterials Materials paper tested QKCMP, a short VEGF-mimicking peptide, as a graft-embedded signal meant to accelerate endothelialization. The idea targets a real failure mode, but the evidence is still early and mostly in vitro.
When GLP‑1s meet pregnancy planning
A 2026 clinical perspectives paper pulls together what’s known (and unknown) about GLP‑1 drugs and fertility, contraception reliability, and pregnancy planning—plus what the drug labels actually say about washout and birth control.
GLP‑1 drugs in type 1 diabetes: the safety signal gets sharper
A huge electronic health record analysis suggests GLP‑1 receptor agonists in type 1 diabetes may be linked to fewer major heart and kidney events without a clear increase in hospitalized DKA—a promising signal that still isn’t a randomized trial.
Hi1a is still hard science—but it just got easier to make
A new paper reports a rapid ‘single-shot’ automated method to chemically synthesize linear Hi1a, a disulfide-rich venom peptide studied for neuroprotection. It’s not a clinical result, but it can remove a real bottleneck.
What people say GLP‑1 side effects feel like (and why Reddit data isn’t the same thing as safety data)
A 2026 medRxiv preprint analyzed 410,198 Reddit posts about semaglutide and tirzepatide. GI symptoms dominated, but the real value is in seeing which experiences people choose to write about—and which clusters might deserve more explicit measurement.
MOTS‑c isn’t a weight-loss switch. It’s a mitochondria signal
MOTS‑c is a real mitochondrial DNA-encoded peptide with intriguing metabolic effects in animal studies, but human evidence is still early and easy to overhype.